ASX Biotech Investing has always been the market’s most difficult arena. Yes tech and resources are risky spaces too, but at least a gold explorer can gain just off the…
07
13
Immutep’s Phase 3 trial for Efti has gotten the chop and shares plunge >90%! What now for investors?
After nearly a week in suspense, Immutep (ASX:IMM) confirmed news about Efti that its investors did not want to hear, and arguably feared more and more as the week with…
07
26
30
